The complete revamp of the ACIP, the CDC's vaccine advisory committee, has diminished its credibility and influence. This has created a vacuum where individual states and professional groups like the American Pediatric Association are now issuing their own vaccination recommendations, fragmenting national public health policy.
Deals like Neurocrin buying Soleno and Servier buying Day One illustrate a trend of mid-sized drug makers becoming significant buyers. This expands the pool of potential bidders beyond just large-cap pharma, creating more competitive M&A processes that can benefit selling companies and their investors.
The FDA's second Complete Response Letter for Replimune's advanced melanoma drug is a disappointing signal for the industry. Despite having what appeared to be a decent risk-benefit profile, the rejection suggests the regulatory bar for approvals based on single-arm studies remains unpredictably high and a head-scratcher for observers.
The administration's proposed 100% tariffs on some pharma companies are more political posturing than substantive policy. The tariffs exclude generics, orphan drugs, and rare disease treatments. Additionally, 16 of the 17 largest pharma companies have already signed deals with the U.S., making them exempt.
Neurocrin's acquisition of Soleno keeps a profitable, commercial-stage asset within the biotech sector (and the XBI ETF), rather than transferring its cash flow to Big Pharma. This trend of profitable biotechs acquiring others makes the sector more attractive to generalist investors who prioritize cash flow, potentially driving valuations.
An SEC filing revealed that Merck's controversial 6% premium for Terns was due to updated, non-public clinical data showing weaker efficacy than previously announced. This new data caused a rival bidder offering $61 plus a CVR to drop out entirely, demonstrating how crucial due diligence data rooms are in M&A.
The FDA's proposed alternative to the Investigational New Drug (IND) pathway aims to speed up Phase 1 trials by leveraging existing preclinical data. A key detail suggests this may rely on validated non-animal methods (NAMS), potentially accelerating development for some drugs but also introducing uncertainty around regulatory acceptance of these newer technologies.
Gilead's $3.15B upfront acquisition of German-based Tubulus for its ADC platform is a notable departure from the recent trend of major pharma companies sourcing ADC technology and assets primarily from China. This deal signals that differentiated ADC platforms from other regions, like Europe, can still command significant value.